MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

Search

Crinetics Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

29.43 3.66

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

28.14

Max

29.95

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-16M

-97M

Pardavimai

361K

361K

Pelnas, tenkantis vienai akcijai

-1.04

Pelno marža

-26,807.202

Darbuotojai

437

EBITDA

-17M

-110M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+162.27% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-467M

2.7B

Ankstesnė atidarymo kaina

25.77

Ankstesnė uždarymo kaina

29.43

Naujienos nuotaikos

By Acuity

50%

50%

163 / 380 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-02 17:03; UTC

Pagrindinės rinkos jėgos

Furniture Companies Rise on U.S. Trade Deal With Vietnam

2025-07-02 15:18; UTC

Pagrindinės rinkos jėgos

Mogo Shares Rally After Embrace of Bitcoin Into Holdings, Operations

2025-07-02 23:45; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-02 23:45; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2025-07-02 23:40; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Hopes for More Trade Deals -- Market Talk

2025-07-02 21:01; UTC

Įsigijimai, susijungimai, perėmimai

AT&T Completes Sale of Entire Remaining 70% Stake in DIRECTV to TPG >T

2025-07-02 21:01; UTC

Įsigijimai, susijungimai, perėmimai

AT&T and TPG Close DIRECTV Transaction

2025-07-02 20:26; UTC

Uždarbis

Rivian Stock Drops on Sales Decline. The Stakes Are High for the Rest of 2025. -- Barrons.com

2025-07-02 20:22; UTC

Rinkos pokalbiai

Gold Rises Following Weak ADP Payroll Reading -- Market Talk

2025-07-02 20:13; UTC

Rinkos pokalbiai

Oil Price Expectations Stable in Dallas Fed Survey -- Market Talk

2025-07-02 19:09; UTC

Rinkos pokalbiai

Oil Futures Bounce in Defiance of Downbeat Data -- Market Talk

2025-07-02 19:08; UTC

Rinkos pokalbiai

Dollar Trims Gains as Investors Brace for Cooling Jobs Market -- Market Talk

2025-07-02 19:01; UTC

Rinkos pokalbiai

U.S. Natural Gas Ticks Up Ahead of Storage Data -- Market Talk

2025-07-02 18:08; UTC

Rinkos pokalbiai

Fossil Fuels Rule Energy Roost As U.S. Marks Independence -- Market Talk

2025-07-02 17:06; UTC

Įsigijimai, susijungimai, perėmimai

BCE: Maple Leafs, Raptors Rights Access Through Long-Term Agreement With Rogers, Subject to League Approvals

2025-07-02 17:05; UTC

Įsigijimai, susijungimai, perėmimai

BCE: Access to Content Rights for Toronto Maple Leafs, Toronto Raptors on TSN Secured Through 2043/2044 Season

2025-07-02 17:04; UTC

Įsigijimai, susijungimai, perėmimai

BCE: Proceeds of MLSE Stake Sale to Support Financing of Acquisition of Ziply Fiber

2025-07-02 17:04; UTC

Įsigijimai, susijungimai, perėmimai

BCE Inc. Concludes Sale of Minority Stake in Maple Leaf Sports & Entertainment

2025-07-02 17:02; UTC

Įsigijimai, susijungimai, perėmimai

Rogers Communications: Now Largest Owner With 75% Interest in Maple Leaf Sports & Entertainment

2025-07-02 17:02; UTC

Įsigijimai, susijungimai, perėmimai

Rogers Communications Closes Deal to Buy BCE's 37.5% Stake in Maple Leaf Sports & Entertainment for C$4.7B

2025-07-02 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-07-02 16:20; UTC

Rinkos pokalbiai

Cushing Crude Stock Slide Keeps Bid in WTI -- Market Talk

2025-07-02 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-07-02 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-02 16:11; UTC

Rinkos pokalbiai

Copper Prices Hold Higher on Supply Disruption, Tariff Uncertainty -- Market Talk

2025-07-02 16:09; UTC

Rinkos pokalbiai

Gold Futures Rise, Recouping Some Losses -- Market Talk

2025-07-02 15:59; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, Centene, Apple, Adobe, Rigetti Computing, Greenbrier, and More -- Barrons.com

2025-07-02 15:17; UTC

Rinkos pokalbiai

Oil Market to Keep Close Watch on U.S. Payrolls -- Market Talk

2025-07-02 15:08; UTC

Rinkos pokalbiai

Luxury Sector Should Report a Slowdown -- Market Talk

2025-07-02 15:00; UTC

Įsigijimai, susijungimai, perėmimai

Glencore: Merger of Viterra With Bunge Global Closed

Akcijų palyginimas

Kainos pokytis

Crinetics Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

162.27% į viršų

12 mėnesių prognozė

Vidutinis 75.43 USD  162.27%

Aukščiausias 97 USD

Žemiausias 60 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

8

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

30.39 / 33.46Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

163 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.